Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Inclusion Criteria: * REGISTRATION INCLUSION * (COHORT 1): Age \>= 18 years * COHORT 1: Laboratory confirmed diagnosis of COVID-19 through confirmation of SARS-Co-V2 via reverse transcriptase polymerase chain reaction (RT-PCR) or any Food and Drug Administration (FDA) approved method. The date of test result is required to be =\< 7 days prior to registration (NOTE: please use the date the test was resulted and NOT the date when the test was collected) * COHORT 1: Patient is on ibrutinib for the following approved FDA indications, including: * Chronic lymphocytic leukemia/Small lymphocytic lymphoma * Mantle cell lymphoma * Waldenstrom macroglobulinemia * Marginal zone lymphoma * COHORT 1: Patients have been on standard dose ibrutinib therapy (420 mg daily for chronic lymphocytic leukemia \[CLL\]/small lymphocytic lymphoma \[SLL\] and Waldenstrom/Waldenstrom macroglobulinemia, and 560 mg daily for mantle cell lymphoma and marginal zone lymphoma) for at least 6 months prior to diagnosis of COVID-19 infection; and there is no evidence of disease progression of the primary malignancy for which ibrutinib is being used * NOTE: Patients are allowed to receive standard treatment as per local institutional guidelines for the treatment of COVID-19 at the same time the patient is enrolled on this trial * COHORT 1: Provide informed written consent =\< 7 days prior to registration * COHORT 1: Willing to return to enrolling institution for follow-up (during the active monitorin…